3 ASX Growth Companies With High Insider Ownership And Up To 60% Earnings Growth

In This Article:

As the ASX200 edges up by approximately 0.6% to 8,198 points amidst mixed sector performances and lower trading volumes due to the Labour Day holiday in some states, investors are closely monitoring global events such as the conflict in the Middle East. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the company best and may offer robust earnings potential even amid market fluctuations.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Clinuvel Pharmaceuticals (ASX:CUV)

10.4%

27.4%

Catalyst Metals (ASX:CYL)

17%

54.5%

Genmin (ASX:GEN)

12%

117.7%

Hillgrove Resources (ASX:HGO)

10.4%

71.5%

AVA Risk Group (ASX:AVA)

15.7%

118.8%

Pointerra (ASX:3DP)

20.1%

126.4%

Liontown Resources (ASX:LTR)

14.7%

49.8%

Acrux (ASX:ACR)

17.4%

91.6%

Adveritas (ASX:AV1)

21.1%

144.2%

Plenti Group (ASX:PLT)

12.8%

106.4%

Click here to see the full list of 98 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Mineral Resources

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Mineral Resources Limited operates as a mining services company with operations in Australia, Asia, and internationally, and has a market cap of approximately A$9.94 billion.

Operations: The company's revenue segments consist of A$0.02 million from Energy, A$1.41 billion from Lithium, A$2.58 billion from Iron Ore, and A$3.38 billion from Mining Services, along with A$0.02 million from Other Commodities.

Insider Ownership: 11.7%

Earnings Growth Forecast: 38.3% p.a.

Mineral Resources, with substantial insider ownership, is navigating financial challenges while pursuing growth. Recent M&A discussions for its Perth Basin assets aim to bolster its balance sheet, following a significant A$1.3 billion asset sale in June. Despite net income decline to A$125 million and increased debt pressures, the company forecasts earnings growth of 38.3% annually over three years, outpacing the Australian market's average. Insider buying activity suggests confidence in future prospects amidst strategic asset evaluations.

ASX:MIN Earnings and Revenue Growth as at Oct 2024
ASX:MIN Earnings and Revenue Growth as at Oct 2024

Mesoblast

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited is involved in the development of regenerative medicine products across Australia, the United States, Singapore, and Switzerland, with a market cap of A$1.70 billion.